MVP (mitomycin, vinblastine, and progesterone): a second-line regimen in ovarian cancer with a high incidence of pulmonary toxicity.
Thirteen patients with epithelial ovarian cancer refractory to primary combination chemotherapy regimens were treated with a three-drug combination called MVP: mitomycin, vinblastine, and progesterone. None of the patients had an objective response to therapy. Five of the 13 patients (39%) developed signs and symptoms consistent with drug-induced pulmonary toxicity following therapy with MVP and histologic confirmation was obtained in two patients. Mitomycin and vinblastine therapy in heavily treated patients with ovarian cancer may be associated with a higher risk of pulmonary toxicity than that previously reported for patients with other tumors.